The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

The world just got a little closer. The new iGlobal Radio App is now live, offering users a dynamic way to connect with radio ...

New analysis of traffic patterns on Toronto's Gardiner Expressway reveals a harsh reality for commuters and commercial fleets alike: ongoing construction is effectively doubling travel times in key ...

The drug is already approved in the EU for transthyretin amyloidosis with polyneuropathy but now covers patients with cardiomyopathy.